Risk based approach for design and optimization of novel tablet for type-II diabetes

Vaishali Thakkar, Hardeep Mahida, Lalji Baldaniya, Mukesh Gohel, Tejal Gandhi, Hitesh Raval, Nirav Patel

Abstract


Objective: The main focus of current investigation was to develop and optimize the manufacturing process of novel tablet containing sustained release Metformin HCl (MET) in core and immediate release Glimepiride (GLIMP) in coating for type II diabetes, by risk assessment approach using Failure Mode Effect Analysis (FMEA) tool.

Methods: Quality risk management (QRM) studies were conducted for each critical process parameters of active coated tablet of MET and GLIMP. A 32 full factorial design was employed for optimization of core tablet of MET to investigate effect of amount of HPMC K100M (A) and HPMC K15M (B) on percent drug release up to 10 hr. GLIMP coating was done on optimize core tablet. A 23 factorial design was used for optimization of coating to investigate the effect of spray rate, inlet air temp., and pan speed on coating parameter. Main effects and interaction plots were generated to study effects of variables. Amount of HPMC K100M and 15M have risk priority number (RPN) 50 and require through investigation and optimization.

Results: The selection of optimized formulation was done on the basis of overlay contour plots and desirability function. The optimized formulation exhibited percent drug release of 30.61, 54.13 and 96.86 at 1, 3 and 10 hr. respectively. Using design of experiment, the optimized conditions selected for coating are spray rate, temperature, pan speed was 3.34 ml/min, 60.60C and 13.2 RPM respectively. The critical quality attributes of unit operations like blending, compression and coating were optimized. The optimized formulations were stable for three months at accelerated and long term stability conditions.

Conclusions: The developed formulation may provide prudently a better substitute for conventional tablet in circumventing its hiccups; improve biopharmaceutical properties, providing sustained and immediate release and may anticipate a better bioavailability and patient compliance

Keywords


Risk based approach, Metformine hydrochloride, Glimepiride, Type II diabetes, Quality target product profile, Critical quality attributes, Risk assessment

Full Text:

PDF HTML XML

References


http://www.who.int/mediacentre/factsheets/fs312/en/

http://www.who.int/topics/diabetes_mellitus /en/

Holman R, Paul S, Bethel M, Matthews D, Neil, H. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New Engl J Med. 2008;359:1577-89.

Dunn C, Peters D. Metformin. Drugs. 1995;49:721-49.

Moses R. Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin. Expert Rev of Endo & Meta. 2010;5:331-42.

Nathan D. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Woo and Eizirik. Diabetes Care. 2009;32:e37-8.

Defang O, Shufang N, Wei L, Hong G, Hui L, Weisan P. In Vitro and In Vivo Evaluation of Two Extended Release Preparations of Combination Metformin and Glipizide. Drug Dev Ind Pharm. 2005;31:677-85.

Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic and pharmacodynamic rationale for oral CR metformin formulation. J Control Release. 2001;71:107-15.

Pharmacologic Management of Type 2 Diabetes. Can J Diabetes. 2013;37:S312-3.

Leichter S, Thomas S. Combination Medications in Diabetes Care: An Opportunity That Merits More Attention. Clinical Diabetes. 2003;21:175-8.

Draft Guidance for Industry: ANDA Submissions — Prior approval supplements. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM176374.pdf

Singh L, Sharma V. Quality by Design (QbD) Approach in Pharmaceuticals: Status, Challenges and Next Steps. Drug Delivery Letters. 2014; (4): 2-8.

Charoo N, Shamsher A, Zidan A, Rahman Z. Quality by design approach for formulation development: A case study of dispersible tablets. Int J Pharm. 2012;423:167-78.

Chileshe N. Quality management concepts, principles, tools and philosophies. J of Eng, Design and Tech. 2007;5:49-67.

Guidance for Industry Q8(R2) Pharmaceutical Development. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf

Vora C, Patadia R, Mittal K, Mashru R. Risk based approach for design and optimization of stomach specific delivery of rifampicin. Int J Pharm. 2013; (455):169-81.

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM304305.pdf

Thwaites P. The effect of mixing time and mixer intensity on the compression properties of tablettose®. Drug Dev Ind Pharm. 1992;18:2001-10.

Perioli L, Ambrogi V, Giovagnoli S, Blasi P, Mancini A, Ricci M. Influence of Compression Force on The Behavior of Mucoadhesive Buccal Tablets. AAPS PharmSciTech. 2008;9:274-81.

Santos J, Batista de, Carvalho L, Pina M. The Influence of the Compression Force on Zidovudine Release from Matrix Tablets. AAPS PharmSciTech. 2010;11:1442-8.

Dubey A, Boukouvala F, Keyvan G, Hsia R, Saranteas K, Brone D. Improvement of Tablet Coating Uniformity Using a Quality by Design Approach. AAPS PharmSciTech. 2012;13:231-46.

Koller D, Hannesschlager G, Leitner M, Khinast J. Non-destructive analysis of tablet coatings with optical coherence tomography. Eur J Pharm Sci. 2011;44:142-8.

Yu L. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharm Res. 2008;25:781-91.

Implementing QbD for biopharmaceutical production processes. Biotech and Bioeng., 2010, 106:845-48.

Bansal S, Beg S, Asthana A, Garg B, Kapil R, Sing B. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride. Drug Deliv. 2014;28:1-15.

Gupta V, Assmus M, Beckert T, Price J. A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. Int J Pharm. 2001;213:93-102.

Barmpalexis P, Kanaze F, Georgarakis E. Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology. J Pharmaceut Biomed. 2009;49:1192-202.

Perioli L, Ambrogi V, Giovagnoli S, Blasi P, Mancini A, Ricci M, et al. Influence of Compression Force on The Behavior of Mucoadhesive Buccal Tablets. AAPS PharmSciTech. 2008;9:274-81.

Vora C, Patadia R, Mittal K, Mashru R. Risk based approach for design and optimization of site specific delivery of isoniazid. J Pharma Invest. 2014;45:249-64.

Rekhi G, Nellore R, Hussain A, Tillman L, Malinowski H, Augsburger L. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. J Control Release. 1999;59:327-42.

Costa P, Sousa Lobo J. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations